Literature DB >> 25611012

8-mm versus 10-mm diameter self-expandable metallic stent in bilateral endoscopic stent-in-stent deployment for malignant hilar biliary obstruction.

Itaru Naitoh1, Takahiro Nakazawa, Tesshin Ban, Fumihiro Okumura, Atsuyuki Hirano, Hiroki Takada, Shozo Togawa, Kazuki Hayashi, Katsuyuki Miyabe, Shuya Shimizu, Hiromu Kondo, Yuji Nishi, Michihiro Yoshida, Hiroaki Yamashita, Shuichiro Umemura, Yasuki Hori, Akihisa Kato, Hitoshi Sano, Takashi Joh.   

Abstract

BACKGROUND: We aimed to clarify the clinical benefits of using 8-mm versus 10-mm diameter self-expandable metallic stent (SEMS) in bilateral endoscopic stent-in-stent (SIS) deployment for malignant hilar biliary obstruction (MHBO).
METHODS: A total of 72 consecutive patients with MHBO treated by endoscopic bilateral SIS deployment were enrolled. The 8-mm and 10-mm diameter SEMSs were used in 37 patients (8-mm group) and 35 patients (10-mm group), respectively. We retrospectively compared technical success, functional success, complications, successful re-intervention, time to recurrent biliary obstruction (RBO) and survival time between two groups.
RESULTS: There were no significant inter-group differences in terms of technical success (8-mm vs. 10-mm group, both 100%), functional success (96% vs. 100%), early (5% vs. 9%) and late (19% vs. 14%) complications other than RBO, and successful endoscopic re-intervention (94% vs. 100%), respectively. Time to RBO (median: 198 days vs. 222 days; log-rank, P = 0.440) and survival time (median: 186 days vs. 235 days; log-rank, P = 0.883) did not differ significantly between the two groups. However, the success rate of endoscopic bilateral revisionary stent insertion for RBO was significantly higher in the 10-mm compared to the 8-mm group (68% vs. 31%; P = 0.044).
CONCLUSIONS: The 10-mm diameter SEMS is more suitable with regard to endoscopic re-intervention.
© 2015 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Bilateral stent; Hilar malignant biliary obstruction; Re-intervention; Self-expandable metallic stent; Stent-in-stent

Mesh:

Year:  2015        PMID: 25611012     DOI: 10.1002/jhbp.219

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  6 in total

1.  SEMS and Sensibility: Self-Expandable Metal Stents for Malignant Biliary Obstruction-Are Stent Characteristics Important?

Authors:  Evangelos Kalaitzakis
Journal:  Dig Dis Sci       Date:  2019-09       Impact factor: 3.199

2.  Placement of a Newly Designed Y-Configured Bilateral Self-Expanding Metallic Stent for Hilar Biliary Obstruction: A Pilot Study.

Authors:  Dechao Jiao; Kai Huang; Ming Zhu; Gang Wu; Jianzhuang Ren; Yanli Wang; Xinwei Han
Journal:  Dig Dis Sci       Date:  2016-09-01       Impact factor: 3.199

Review 3.  Update on Pancreatobiliary Stents: Stent Placement in Advanced Hilar Tumors.

Authors:  Sung Ill Jang; Dong Ki Lee
Journal:  Clin Endosc       Date:  2015-05-29

4.  Endoscopic reintervention for stent malfunction after stent-in-stent deployment for malignant hilar obstruction.

Authors:  Joung Boom Hong; Dae Hwan Kang; Hyeong Seok Nam; Cheol Woong Choi; Hyung Wook Kim; Su Bum Park; Su Jin Kim; Woo Hyeok Choi
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

5.  Clinical Outcomes of Bilateral Stent-in-Stent Placement Using Self-Expandable Metallic Stent for High-Grade Malignant Hilar Biliary Obstruction.

Authors:  Ja Yoon Heo; Hee Seung Lee; Jun Hyuk Son; Sang Hyub Lee; Seungmin Bang
Journal:  Yonsei Med J       Date:  2018-09       Impact factor: 2.759

6.  Factors Associated with the Technical Success of Bilateral Endoscopic Metallic Stenting with Partial Stent-In-Stent Placement in Patients with Malignant Hilar Biliary Obstruction.

Authors:  Toshihiro Fujita; Shinichi Hashimoto; Shiroh Tanoue; Kengo Tsuneyoshi; Yoshitaka Nakamura; Makoto Hinokuchi; Hiromichi Iwaya; Shiho Arima; Yuji Iwashita; Fumisato Sasaki; Hiroki Taguchi; Shuji Kanmura; Akio Ido
Journal:  Gastroenterol Res Pract       Date:  2019-09-16       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.